Deutsch
A A A
DE
Bereichsnavigation

Previous
Corporate News | 05/06/2016

RHÖN-KLINIKUM AG: Interim Report for the First Quarter of 2016: financial year starts well - strategic focus on digitalisation and promoting innovation

DGAP-News: RHÖN-KLINIKUM AG / Key word(s): Quarter Results/Quarter Results2016-05-06 / 07:00 The issuer is solely responsible for the content of this announcement.


Corporate News

Interim Report for the First Quarter of 2016: financial year starts well - strategic focus on digitalisation and promoting innovation

- 205,578 patients treated

- Revenues stand at EUR 291.5 million

- EBITDA of approx. EUR 68 million includes positive one-off effect of roughly EUR 36 million

- Outlook for 2016: Revenues between EUR 1.17 billion and EUR 1.20 billion,EBITDA between EUR 155 million and EUR 165 million

Bad Neustadt / Saale, 6th May 2016

In the first quarter of the current financial year over 200,000 (205,578 to be precise) patients were treated in the hospitals of RHÖN-KLINIKUM AG. Revenues for the same period amounted to EUR 291.5 million with earnings before interest, taxes, depreciation and amortisation (EBITDA) standing at EUR 67.9 million. This also includes a positive special influence in the amount of EUR 36.4 million after dissolving provisions for warranty claims from the sale of a total of 43 facilities to Helios/Fresenius which was completed in 2014. The current financial figures are therefore not directly comparable with those of previous years due to these ongoing effects on the balance sheet.

Annual General Meeting on 8th June 2016

The Board of Management and Supervisory Board shall propose to this year's ordinary Annual General Meeting on 8th June 2016 in Frankfurt/Main the distribution of a dividend in the amount of EUR 0.80 per non-par share. This results in a dividend amount of almost EUR 54 million based on the current number of roughly 67 million shares. RHÖN-KLINIKUM AG also intends the shareholders to be able to participate extensively in the future success of the Company by means of dividend payout ratios which are above 60 %, thereby allowing the Company to remain in M-Dax with an attractive dividend value.

Outlook

For financial year 2016 we expect revenues of EUR 1.17 billion to EUR 1.20 billion and earnings before interest, taxes, depreciation and amortisation (EBITDA) of between EUR 155 million and EUR 165 million. Positive and negative one-off effects, the size of which will be a low to medium two-digit million figure, will continue to influence the corporate results during this financial year as well and will partially cancel each other out. They mainly result from handling the transaction with Fresenius/Helios, the initial consolidation and integration of the municipal hospital in Bad Neustadt, special budgets for innovation and e-health, unresolved accounting issues and setting up a substantial out-patient clinic at the university hospital in Marburg. We assume that regulatory restrictions will also have a negative impact on our organic growth in 2016. Against this background we must expect a drop in revenues of roughly 1 % for the current financial year.

"With an extensive number of initiatives and measures we are pressing ahead with the digitalisation process in our Company and are also investing in targeted innovation in order to provide our patients with the best possible medical care together with a direct link to university standards, also with an eye to the future," Dr. Martin Siebert stated. The pioneering role in both areas is also a precondition for pressing ahead with the campus concept. "We are now placing greater emphasis on the link between in-patient and out-patient medical care including other areas, such as rehabilitation, in order to ensure long-term, first-class medical care for our patients who are particularly in rural areas. We shall also continue to strengthen and develop this unique position which we have in the market," Siebert continued.

***************************************************************************************

RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. At five medical sites with a total of 5,400 beds we offer cutting-edge medical care with a direct link to universities and research institutes. Our top five key areas of treatment are cardiological and coronary disease, neurological disorders, oncology, lung diseases as well as orthopedic and accident surgery. A total of over 16,000 employees work for RHÖN-KLINIKUM AG. Our facilities are located in Bad Berka, Bad Neustadt/Saale, Frankfurt (Oder) and Giessen and Marburg.

Further information is available at: www.rhoen-klinikum-ag.com

Your Contact Persons:

RHÖN-KLINIKUM AG

Achim StruchholzHead of Corporate CommunicationSchlossplatz 197616 Bad Neustadt / SaaleT. + 49 - 9771 65-1327F. + 49 - 9771 65-1820kommunikation(at)rhoen-klinikum-ag.com Dr. Kai G. KlingerHead of Investor Relations & Group FinancingSchlossplatz 197616 Bad Neustadt / SaaleT. + 49 - 9771 65-1318F. + 49 - 9771 99-1736ir(at)rhoen-klinikum-ag.com


2016-05-06 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English
Company: RHÖN-KLINIKUM AG
Salzburger Leite 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart; Terminbörse EUREX
End of News DGAP News Service